NCT02151656已完成2 期
Effects of F17464 in Acute Exacerbation of Schizophrenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 158
- 主要终点
- Change of the Positive and Negative Syndrome Scale (PANSS) total score
研究概览
简要总结
The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Study design: double-blind, randomized, placebo-controlled, parallel-groups, fixed-dose design, multicentre study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Demographic and other characteristics
- •Male or female, 18-64 years of age inclusive
- •primary diagnosis of schizophrenia undergoing an acute exacerbation with prominent "active phase" symptoms, as described by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition - Text Revision (DSM IV-TR) using the MINI 6.0 (Mini-International Neuropsychiatric Interview) for schizophrenia and psychotic disorders related to DSM IV-TR
- •Well-documented diagnosis of schizophrenia for a minimum of 1 year before the screening visit
- •Since the diagnosis of schizophrenia, the average number of hospitalisations should be no higher than 2 per year (the minimum duration of hospitalization should be more than 4 days)
- •During the year before Visit 1, maximum 3 acute psychotic episodes that required hospitalization or change of antipsychotic medication or other therapeutic intervention
- •Adequate clinical response to well-conducted treatment courses during previous acute episodes. A well conducted treatment course is defined as an antipsychotic treatment with the usual doses for at least 4 weeks
- •Current acute episode
- •Structured Clinical Interview for the Positive And Negative Syndrome Scale (SCI-PANSS) with a PANSS total score ≥ 70 to < 120 (at Visit 1 and 2)
- •Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms: delusions, hallucinatory behaviour, conceptual disorganization, suspiciousness/persecution
- •Clinical Global Impression of Severity (CGI-S) score ≥ 4 (moderate or severe)
- •Antipsychotic initiated for this acute episode and/or ongoing chronic antipsychotic treatment, with a maximum of 2 antipsychotics in total needed to be changed (due to inefficacy or safety reasons)
- •Hospitalization and/ or treatment for the current psychotic episode for less than 2 weeks prior to Visit 1
- •No significant improvement of PANSS total score between enrolment (Visit 1) and inclusion (Visit 2) corresponding to a score improvement < 20% on positive symptoms subscale
排除标准
- •Related to the pathology
- •Patients in their first acute episode of psychosis
- •Current schizophrenic episode with predominant negative symptoms
- •Patient " known to be refractory " defined as lack of significant improvement (no significant relief of symptoms, and no period of good function) despite adequate courses with at least 3 different antipsychotics medication cycles of an adequate duration (at least 4 weeks) and at adequate dosage during the previous 5 years;
- •Schizoaffective disorder, schizophreniform disorder and other psychotic disorders;
- •Bipolar I and II disorder
- •Pervasive developmental disorder, mental retardation, delirium, dementia, memory impairment and other cognitive disorders that would compromise a reliable assessment according to the investigator's opinion
- •Known or suspected borderline or antisocial personality disorder or other DSM IV axis II disorder of sufficient severity to interfere with participation in this study
- •History of tardive dyskinesia or chronic extra-pyramidal symptoms (EPS), serotonin syndrome or neuroleptic malignant syndrome
- •Major depressive disorder which requires a pharmacological treatment
- •At imminent risk of injuring him/herself or others or causing significant damage to property, as judged by the investigator
- •Suicidal risk based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
- •Any suicidal behavior in the past year
- •Suicidal ideation of type 4 or 5 in the past month
- •Related to treatments
- •Structured psychotherapy (e.g. cognitive behavioural therapy) started within 6 weeks before visit 1
- •Electroconvulsive therapy within 3 months before Visit 1
- •Previous lack of response to electroconvulsive therapy
- •Treatment ongoing with a depot neuroleptic (even if less than 1 cycle in duration before Visit 1)
- •Patient having previous treatment course with clozapine within the 4 months prior to Visit 1
- •Requirement of concomitant treatment with any of the prohibited medications
- •History of intolerance or hypersensitivity to other drugs of the same chemical class as F17464 or to rescue medications or any history of severe drug allergy or hypersensitivity
研究组 & 干预措施
F17464
Experimental
Oral administration - During 6 weeks - 4 capsules daily
干预措施: F17464 (Drug)
Placebo
Placebo Comparator
Oral administration - During 6 weeks - 4 capsules daily
干预措施: Placebo (Drug)
结局指标
主要结局
Change of the Positive and Negative Syndrome Scale (PANSS) total score
时间窗: Day 43
Change from baseline to Day 43 of the PANSS total score
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
不适用
Effects of F17464 in acute exacerbation of schizophrenia.MedDRA version: 17.1Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersschizophreniaEUCTR2013-005451-32-HUPierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)142
进行中（未招募）
1 期
Effects of F17464 in acute exacerbation of schizophrenia.schizophreniaEUCTR2013-005451-32-ROPierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)142
进行中（未招募）
1 期
Effects of F17464 in acute exacerbation of schizophrenia.schizophreniaEUCTR2013-005451-32-LVPierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)142
终止
2 期
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative SymptomsSchizophrenia, Schizoaffective DisorderNCT03669640Hoffmann-La Roche131
已完成
2 期
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.SchizophreniaNCT00616798Hoffmann-La Roche323